Abstract: Functional mitral regurgitation (MR) is a common clinical entity which will likely increase in the future due to predicted demographic changes. It is also associated with poor long-term survival. The anatomic structure of the mitral valve apparatus is complex and consists of several components, each of which can be affected by a variety of diseases resulting in MR. In primary MR, the valvular incompetence is caused by compromised or structurally disrupted components of the valve apparatus; the valve in functional MR is structurally normal, with the regurgitation resulting from failure of coaptation of the mitral valve leaflets without coexisting structural changes of the valve itself. Therefore, we defined functional MR as a systolic retrograde flow from the left ventricle into the left atrium due to reduction and/or elimination of the normal systolic coaptation of the mitral valve leaflets. A slow progression of the symptoms is typical for this valve disease and often ends in irreversible left ventricular dysfunction. The pathophysiology and treatment of functional MR are quite complex. This article reviews and summarizes the existing literature, with a focus on the pathophysiology and current treatment of functional MR.
M
itral valve regurgitation (MR), defined as retrograde flow from the left ventricle (LV) into the left atrium during systole, is among the most common valve diseases in developed countries and represents nearly one-third of acquired left-sided valve pathology. 1 MR can be broadly classified into 2 major categories as follows: primary and secondary MR. In primary MR, the valvular incompetence is caused by compromised or structurally disrupted components of the valve apparatus. Examples include degeneration from rheumatic disease, myxomatous degeneration, endocarditis, chordae tendineae rupture, and papillary muscle rupture. In secondary MR, the valve is structurally normal with the regurgitation resulting from failure of coaptation of the mitral valve leaflets without coexisting structural changes of the valve itself. This form of MR is often referred to as functional MR.
The pathophysiology of primary MR is well understood. The incompetent valve causes volume overload in the LV, leading to ventricular remodeling, myocardial dysfunction, and ultimately, heart failure. The treatment of primary MR is clearly defined by American College of Cardiology/American Heart Association guidelines. 2, 3 On the other hand, the pathophysiology and treatment of functional MR is more complex and controversial. There is a growing general consensus that functional MR evolves from a primarily ventricular (and not valvular) etiology, of any type, that first causes ventricular dilatation. Ventricular dilatation in the setting of a structurally normal valve then causes the papillary muscles to be situated too far apart, typically leading to a central area of failed coaptation and subsequent MR. The optimal therapeutic strategy for functional MR is currently a topic of substantial debate. Specifically, it is unclear whether treatment should involve intervention on the valve (ie, mitral valve repair or replacement), correction of ventricular pathology, both, or neither. Further complicating this issue is the fact that there have been varying definitions of functional MR used by different investigators in the past, resulting in heterogeneous patient groups that complicate the comparison of outcomes among studies.
In this article, we review and summarize the existing literature, with a focus on the pathophysiology and current treatment of functional MR.
ANATOMY
The mitral valve apparatus is a complex structure composed of 6 functional components, each of which can be affected by a variety of diseases resulting in MR 4 : (1) anterior and posterior mitral valve leaflets; (2) primary, secondary, and tertiary chordae tendineae; (3) anterolateral and posteromedial papillary muscles; (4) the mitral annulus; (5) the left ventricular myocardium, from which the papillary muscles originate, and (6) the left atrial endocardium, from which the posterior mitral leaflet extends.
In primary MR, such as in myxomatous degeneration, more than 1 component is typically involved. With disease progression, other anatomic components may become affected as well. In contrast, with functional MR only the mitral annulus, abnormally dilated, is affected without pathology of any other components of the valve. Such annulus dilatation leads to failure of the normal systolic coaptation between anterior and posterior mitral valve leaflets, resulting in MR. In addition to annular dilation, it is important to note that papillary muscle splaying also results in MR. For this reason, echocardiography remains an important diagnostic tool to assess leaflet tethering.
EPIDEMIOLOGY
The epidemiology of MR has changed in the last several decades, particularly in developed countries. About 50 years ago, rheumatic fever was the leading cause of MR. However, the substantial reduction in rheumatic heart disease and the significant increase of coronary artery disease have altered the epidemiology of MR. The main etiologies of MR today are classified as degenerative, dilatative, and ischemic. [5] [6] [7] Due to the varying definitions of functional MR in the published literature, its prevalence has been difficult to calculate. [5] [6] [7] Some estimates report that up to 40% of patients with heart failure caused by dilated cardiomyopathy (DCM) will develop functional MR. [5] [6] [7] DCM is a disorder of the cardiac muscle in which myocyte weakness leads to ventricular dilatation and heart failure. There are multiple etiologies of DCM, including ischemic, genetic, toxic, viral, inflammatory, autoimmune, and idiopathic causes. 8 -14 As a broad category, DCM has an incidence of 5 to 10 patients/100,000 [15] [16] [17] and a prevalence of 36 patients/100,000 people. 15, 18 Future demographic changes, such as an aging population and greater life expectancy, are expected to increase the incidence of DCM and as a result, the incidence of functional MR. Thus, functional MR will likely play a growing economic and medical role in the coming years.
PATHOPHYSIOLOGY
The pathophysiologic mechanisms are quite different in primary and functional MR. In primary MR, the incompetent valve causes acute and/or chronic LV volume overload, leading to ventricular remodeling, myocardial dysfunction, and subsequent heart failure. In functional MR, on the other hand, a primary ventricular pathology leads to ventricular remodeling and dysfunction with subsequent development of regurgitation through an anatomically normal valve. Specifically, the ventricular remodeling and enlargement causes dilation of the mitral valve annulus. This leads to a reduction or elimination of the normal systolic coaptation line between anterior and posterior mitral valve leaflets, thus compromising competence of mitral valve closure. The resulting regurgitation back into the left atrium during systole increases left atrial volume and pressure. Over time, this chronically increased preload leads to enlargement of the left atrium. In contrast to acute regurgitation where the left atrium is mostly noncompliant, the enlarged left atrium in functional MR is compliant and the V-wave is often smaller.
The degree of MR can be categorized by the effective regurgitant orifice (ERO) area 19 and volume overload, measured as regurgitant volume. This may be affected by the driving force, or LV systolic pressure, and left atrial compliance. 20 In functional MR, the ERO area is dynamic during systole, particularly during the relaxation phases when there is inadequate leaflet apposition due to reduced LV systolic pressure. 21 Changes in myocardial loading or contractility can also affect the ERO area: decreased loading 22 or inotrope administration can cause a reduction or even elimination of the ERO area, whereas exercise most often results in an increase. 23 The total impedance to ventricular ejection is reduced in functional MR since the LV ejects blood through 2 orifices simultaneously: through the aortic valve (forward stroke volume) into the aorta and through the incompetent mitral valve (regurgitant stroke volume) into the lower pressure left atrium. As a consequence, the LV decompresses as blood is ejected into the left atrium and the LV volume declines during isometric contraction and early systole. Thus, in the presence of functional MR, there is no isometric phase of ventricular systole and almost 50% of the regurgitant volume into the left atrium occurs prior to the opening of the aortic valve.
The resultant reduction of impedance enhances LV systolic pump function in early functional MR. Furthermore, this early systolic ventricular emptying into the left atrium leads, according to the Law of Laplace, to a reduction of ventricular wall stress because of the reduction in late systolic LV radius and pressure. The reduction in wall stress, in turn, permits a greater extent and rate of LV systolic shortening, and total stroke volume is increased for any given level of preload (end-diastolic volume) and contractility. It is important to note that in MR the forward, or effective, stroke volume is less than the total stroke volume (forward plus regurgitant). Accordingly, the LV end-diastolic volume and total stroke volume must be increased to fulfill normal circulatory demands. A clinical corollary is that the reported ejection fraction (EF) in these patients often represents a combination of both forward and regurgitant flow.
If the regurgitation continues to progress, further changes in cardiac pathophysiology develop: the left atrium dilates and atrial pressure increases, which results in a higher myocardial afterload, greater end-systolic volume, and consequently, increased ventricular systolic wall stress. 24 As the atrial pressure becomes greater and the driving force, or LV systolic pressure, decreases, the regurgitant volume falls. 25 As a result, functional MR can be clinically silent. 26 Ventricular dysfunction can be associated with large end-systolic dimensions 27, 28 but is often masked by an increased ejection volume; thus, ventricular dysfunction should be suspected with greater than normal end-systolic dimensions even when the EF appears normal. This phenomenon is often revealed only after surgical elimination of MR, when there is an immediate postoperative drop in EF of approximately 10%. 29, 30 In addition, the LV compensates for the chronic hemodynamic volume overload by developing eccentric ventricular hypertrophy. There are substantial variations in the geometric distribution of this compensatory hypertrophy among individuals with the same valvular disease.
Over time, chronic functional MR can also lead to pulmonary hypertension 31 and heart failure. 32, 33 During the progression of heart failure, impaired LV function and remodeling are associated with papillary muscle apical displacement and mitral annular enlargement. This results in decreased mitral closing forces and tenting of the mitral valve, both of which promote MR and thus lead to a vicious cycle (Fig. 1) . Active myocardial ischemia, myocardial asynchronism, and excessive loading conditions worsen MR at rest and during exercise. Other factors that may contribute to the development and progression of functional MR include intraventricular delay and LV dyssynchrony, which can create uncoordinated regional LV mechanical activation or reduce the sphincteric function of the mitral annulus, thereby decreasing the efficiency of LV contraction and closing forces.
In summary, the pathophysiology of functional MR results from a dynamic interplay between chamber pressures, myocardial forces, and cardiac morphology. Some of the significant changes observed in functional MR include annulus enlargement, papillary muscle displacement, reduced mitral closing forces, mitral valve tenting, decreased forward stroke volume, increased left atrial volume and pressure, increased pulmonary arterial and venous pressures, eccentric ventricular hypertrophy, and ventricular remodeling. A vicious cycle is created in which ventricular remodeling, from any etiology, begets MR, which then begets more remodeling. 34 
DIAGNOSIS
Evaluation of the patient's medical history and a careful physical examination are the first and most useful diagnostic tools and may, by themselves, lead to the clinical diagnosis of MR. Echocardiography is the second most useful technique for evaluating patients with MR. According to American College of Cardiology/American Heart Association guidelines, 2-dimensional and Doppler echocardiography is indicated for all patients with suspected MR to confirm its presence and determine its severity (according to the Functional Class). 2 Evaluation of the severity of functional MR on echocardiography requires an integrated assessment of several parameters, including cardiac chamber size and volume, regurgitant jet size by color Doppler, regurgitant jet density by continuous-wave Doppler, and pulmonary vein and mitral valve inflow by pulse-wave Doppler. 20 Newer applications of Doppler echocardiography allow quantitative measurement of MR, including the regurgitant volume and the regurgitant orifice area. Color Mmode can show early systolic or bimodal (early and late systolic) peak MR, corresponding to those time points when there is maximal imbalance between closing and tethering forces on the mitral valve leaflets. Chordal tethering can cause kinking of the anterior leaflet in its midbelly, resulting in the characteristic "seagull" sign on echocardiography. In asymptomatic patients with significant MR, serial echocardiography every 6 to 12 months to assess LV size and systolic function is important for optimal timing of surgery (Class I).
2 Stress echocardiography may also be useful in these patients to assess exercise tolerance and the response of MR severity, pulmonary pressure, and contractile reserve to exercise (Class IIa). 2, 35 Cardiac catheterization and angiography are usually reserved for patients in whom noninvasive test results are inconclusive and also to detect concomitant coronary artery disease in patients undergoing mitral valve surgery (Class I).
2 Additional studies such as cardiac magnetic resonance imaging are helpful to identify viable myocardium (ischemic and hibernating myocardium) and may support the investigation of surgical candidates with functional MR associated with ischemic cardiomyopathy.
PROGNOSIS
The presence of functional MR in patients suffering from ischemic and DCM confers a worse prognosis, serves as an independent risk factor for cardiovascular morbidity and mortality, and limits survival in a severity-graded fashion. 35 Trichon et al examined 2057 patients with ischemic MR and LV systolic dysfunction and were able to correlate MR presence and severity with long-term survival. 36 This group revealed MR to be an independent predictor of mortality and also found significantly lower survival rates at 1, 3, and 5 years in heart failure patients with moderate to severe MR versus those with mild or absent MR. Similar results were presented by Cioffi et al in 2005. 37 This group established the direct and independent relationship between MR severity and 1-year mortality among elderly patients with systolic heart failure, and showed that MR was the strongest predictor of death, independent of the presence of diabetes mellitus, older age, and larger LV end-diastolic volume. However, in this study, MR did not provide useful information regarding the risk of subsequent hospitalization for worsening heart failure. 37 Larger studies have revealed similar results and have shown that patients with functional MR have a worse prognosis than patients with coronary artery disease and no functional MR. A study of 11,748 cardiac catheterization patients revealed 1-year mortality of 40% associated with severe MR, 17% for moderate MR, and 10% for mild MR. 38 If no functional MR was present at catheterization, the 1-year mortality rate was 6%. Data from trials of thrombolysis for acute myocardial infarction showed similarly poor prognosis for functional MR. 39 Postmyocardial infarction patients have a 1-year mortality rate of 52% if they have severe MR, 22% if they have mild-moderate MR, and 11% if they have no MR. The Survival and Ventricular Enlargement study demonstrated that mild functional MR increases the risk of cardiovascular mortality, even in patients without congestive heart failure. 40 Patients with functional MR had a higher incidence of cardiovascular mortality (29% vs. 12%) and heart failure (24% vs. 16%) than patients without MR at a mean of 3.5 years after myocardial infarction. Adjustment for differences in baseline characteristics revealed that mild-to-moderate MR strongly predicted mid-term mortality.
40

TREATMENT OF FUNCTIONAL MITRAL REGURGITATION
The management of functional MR is both challenging and controversial. In particular, there is considerable debate and uncertainly regarding the optimal approach, timing, and effectiveness of surgical intervention for functional MR. Various treatment strategies for functional MR are described below, followed by a discussion of possible future directions.
Medical Treatment
Optimal medical management is mandatory. The prognosis of functional MR and DCM has improved significantly over the last few decades mainly as a consequence of developments in medical treatment options, including angiotensin-converting enzyme inhibitors, beta-blockers, digitalis, diuretics, and vasodilators. The goal with medical therapy is to optimize cardiac performance, reduce symptoms, and enhance survival by unloading the LV and maintaining euvolemia. When symptoms occur despite medical therapy or LV dysfunction occurs, surgery is indicated before LV function becomes substantially more abnormal.
Surgical Treatment
Surgical therapy plays a major role in the treatment of functional MR and should be considered in any symptomatic patient or the asymptomatic patient with decreased LV function. Surgery can often restore quality of life as well as restore life expectancy. 41, 42 Early detection and assessment of MR have direct consideration on surgical therapy. 2, 3, 43 The challenges facing the management of functional MR include an elderly population, multiple comorbidities, timing of the operation, and the increased incidence of heart failure. 1 Although newer interventional techniques, such as minimally invasive percutaneous valve repair, are currently under investigation, mitral valve repair or replacement remains the preferred method to treat severe functional MR in most cardiac centers. With ongoing clinical trials, treatment guidelines will continue to evolve.
The major surgical therapeutic options for functional MR include mitral valve replacement, mitral valve repair, undersized mitral annuloplasty, resynchronization therapy, implanted cardioverter defibrillators, and others. 44 -60 In the setting of severe LV-dysfunction and MR, mitral valve surgery has demonstrated symptomatic improvements and survival benefits. 61 Moreover, several studies have demonstrated that preservation of the annulo-papillary muscle continuity obtained with mitral valve repair or replacement preserves systolic and diastolic LV-function and improves LV geometry and wall stress. 34, [62] [63] [64] In studies of patients with DCM and functional MR, mitral valve surgery led to an improvement in mean New York Heart Association functional class from 3.9 to 2.0, and actuarial survival was 82% at 1 year and 72% at 2 years.
65,66
Mitral Valve Replacement
Mitral valve replacement with either a biologic or mechanical prosthesis was the preferred surgical approach for severe functional MR in early studies. This treatment method involved complete excision of the subvalvular apparatus, but subsequent studies revealed a detrimental effect on LV function and high mortality rates. 67 As a result, various surgical techniques were developed to preserve the entire subvalvular apparatus. Given the thin and pliable
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Functional Mitral Regurgitation valve leaflets and chordae, preserving the entire subvalvular apparatus resulted in maintenance of annulo-ventricular continuity and improved preservation of LV function. 68 Mitral valve replacement remains a reasonable surgical option predominantly because of its reliability and reproducibility. However, this should be considered for high-risk patients with multiple comorbidities, complex regurgitant jets (multiple or noncentral jets), failure of mitral valve repair techniques, or severe tethering of both valve leaflets. 7, 69, 70 Calafiore et al 69 recommend mitral valve replacement when the distance between the coaptation point of the leaflets and the plane of the mitral annulus exceeds 10 mm.
Mitral Valve Repair
The dissatisfying results of mitral valve replacement performed 10 to 20 years ago led surgeons to favor mitral valve repair for functional MR. Several techniques have been reported, eg, undersized annuloplasty, edge-to-edge repair (Alfieri correction) and/or papillary muscle repositioning, and are successfully used with the aim of preserving the mitral valve apparatus. 71 To date, there have been several retrospective studies, but no randomized trials, comparing mitral valve repair to replacement for functional MR. [71] [72] [73] [74] The 2 largest retrospective studies are those by Gillinov et al 70 and Grossi et al. 75 These investigators demonstrated that both mitral valve repair and replacement were effective at eliminating MR immediately postoperatively, but mitral valve repair was associated with lower perioperative mortality. However, high-risk patients with severe MR did as well and possibly better with mitral valve replacement. 7, 70 Regardless of which surgical technique was employed, 5-year survival rates were uniformly disappointing at approximately 50%. 70, 75 The general consensus in the cardiac surgery community appears to be that mitral valve repair results in lower perioperative mortality than replacement and should be performed whenever possible over replacement. 69 Along with this consensus is the acknowledgment, however, that repair may confer a greater risk of MR recurrence. A recent study by Al-Radi et al confirmed a lower perioperative mortality for mitral valve repair in patients with chronic functional MR. The survival advantage decreased over time, however, and was no longer apparent 5 years after surgery. 76 In spite of the optimism generated by some studies, a recent retrospective report showed no demonstrable decrease in long-term mortality with mitral valve repair in patients affected by severe MR and considerable LV dysfunction. 77 These results reflect the heterogeneous nature of the disease and the etiology of MR, which is secondary to ventricular dysfunction and not to organic disease of leaflets. Moreover, these findings indicate that myocardial factors are fundamental determinants of outcome in patients with DCM and that any mitral repair based only on annuloplasty without addressing myocardial remodeling typically result only in a temporary reduction in the severity of MR, with no effect on patient outcome.
In consideration of these findings, other groups have developed several surgical strategies for the treatment of MR secondary to ischemic cardiomyopathy. The first is based on the relocation of posterior papillary muscle tip to treat type IIIb leaflet motion abnormalities. 77 This procedure is based on the observation that the displacement of the posterior papillary muscle tip after posterolateral ischemia is the main mechanism of ischemic MR. 52 The second procedure consists of the cutting of second-order chordae tendineae to the anterior leaflet that has been shown to improve coaptation and reduce MR.
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Undersized Mitral Annuloplasty
Undersized mitral annuloplasty is the most common surgical procedure performed for functional MR, either alone or as part of a complex repair. The rationale of this procedure, first popularized by Bolling et al using very small (size, 24 -26 mm) rings, is that undersizing the mitral annulus will result in increased leaflet coaptation and decreased regurgitation. 65 Although this procedure does not fully address the ventricular causes of functional MR, it is relatively easy to perform and will lead to symptomatic improvement. Mitral valve annuloplasty can be performed with partial rigid rings or complete rigid rings; however, differences in ring design have not yet demonstrated significant differences in clinical outcome. 79 Although this procedure has been widely accepted by the cardiac surgery community, several questions remain unanswered. For example, current evidence does not reveal any definite advantage in terms of size or type of annuloplasty ring. 80 Although the initial results for undersized mitral annuloplasty were encouraging with low perioperative mortality rates, subsequent studies at various centers revealed significant recurrence of MR during follow-up, 66, [81] [82] [83] and that recurrence is always associated with continued LV remodeling and retethering.
Cardiac Resynchronization Therapy
Cardiac resynchronization therapy (CRT) is widely performed as a treatment option for functional MR in cases of severe heart failure and advanced LV dysfunction. Selected patients (heart failure with an EF Ͻ 30%, right ventricular (RV)-LV-dyssynchrony, left bundle branch block, and QRS-time Ͼ120 ms) benefit from CRT.
Mechanical RV-and LV-dyssynchrony in chronic heart failure plays an increasingly important role in the pathophysiological mechanisms of functional MR. It must be noted that both intra-and interventricular LV dyssynchrony may exist, and each plays an important role in the pathophysiology of functional MR. Because of this, important mapping techniques (eg, TSI) are used to confirm that the LV lead is placed in the most optimal portion of the LV (the area of latest mechanical activation), to reduce the MR.
The acute effects of CRT on functional MR were evaluated by Breithardt et al. 84 In their study of 24 patients with biventricular pacemakers, active CRT was associated with almost a 50% reduction in the ERO area (25-13 mm 2 ), which resulted from more coordinated LV contraction. Long-term benefits were noted in the Cardiac Resynchronization-Heart Failure (CARE-HF) and Multicenter InSync Randomized Clinical Evaluation (MIRACLE) randomized trials of CRT. 85, 86 Compared with controls, CRT produced significant reductions in LV end-systolic and end-diastolic dimensions and in MR jet area (eg, Ϫ2.7 vs. Ϫ0.5 cm 2 at 6 months in MIRACLE). 86 However, the benefits of CRT rapidly wane if therapy is discontinued. The magnitude of this effect was illustrated in a report of 20 patients with advanced heart failure who had been on CRT for a median of 427 days. 87 At 72 hours after elective temporary cessation of biventricular pacing, there were significant increases in mitral ERO area (4.8 -9.1 mm 2 ) and MR volume (7.8 -16.0 mL) and regurgitant fraction (13.8%-27.7%). These changes were associated with a significant and marked decline in the maximal rate of rise of LV systolic pressure (711-442 mm Hg/s).
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DISCUSSION
The timing, type, and advantages of surgical correction for functional MR in DCM are still not clear. The operative risk is mitigated by continued vigorous medical management and judicious perioperative care. However, correction of functional MR and the volume overload in a timely fashion can lead to improvement in the physiology and perhaps a reversal of LV dysfunction. When operative treatment is under consideration, the chronic, often slowly progressive nature of MR must be balanced against perioperative morbidity and mortality and the long-term uncertainties of mitral valve surgery. Perioperative morbidity and mortality depend on surgeon experience, the patient's clinical and hemodynamic status, and the presence of associated noncardiac diseases, rather than on which prosthetic or tissue valve or ring is used.
The optimal timing of surgery for patients with severe functional MR has not yet been determined, nor has the optimal surgery for this disease been defined. The difficulty in timing a valve operation in chronic functional MR is complicated by the fact that disabling symptoms may be the result of irreversible LV dysfunction. Clearly, the best time to intervene in functional MR is before irreversible impairment of LV function occurs. Unfortunately, this point cannot be determined by symptoms. Furthermore, the ejection phase indices commonly used to assess LV performance are augmented by the reduced impedance to LV ejection associated with MR. As the LV enlarges and performance decreases, a point is reached where mitral valve surgery likely will not be beneficial. With our current medical knowledge, it is not possible to define this point prospectively in each patient. Our current practice is to offer surgery when there is severe MR, whether there are symptoms or not. For patients with at least moderate MR and symptoms or LV dysfunction, surgery is also offered.
Clinical outcomes of mitral valve surgery in nonischemic DCM are comparable with cardiac transplantation in the early-tointermediate term, but the long-term results are less satisfactory. At the Mayo Clinic, patients undergoing mitral valve repair have a 1-, and 3-year survival of 84% and 80%, respectively. 85 Evolving technology and research focused on methods of altering or reversing cardiomyopathy, eg, cell transplant, may have significant impact on the future management of this debilitating illness. 88 In our opinion, surgical correction of functional MR can be safely performed even when the LV EF is Ͻ30%. Mitral valve repair, especially undersized annuloplasty, can be useful in these patients, but as mentioned above, the indications are still controversial. The benefits of the simplest and shortest procedure must be balanced against potential perioperative complications. Furthermore, in functional MR the treatment of ventricular myocardial damage should be considered as the priority; rather than performing mitral valve repair as an isolated intervention, patients should undergo a concomitant procedure (ie, coronary artery bypass graft) that targets the dysfunctional ventricle.
The correction of functional MR with mitral valve surgery often results in symptomatic improvement, but survival benefit has yet to be proven. Surgical intervention for functional MR, specifically mitral valve repair, is a viable option for symptomatic patients including those with severely depressed LV function, and should be performed as part of an overall therapeutic strategy that targets the underlying ventricular pathology.
One of the most controversial and interesting topics regarding surgery for functional MR is the issue of undersized annuloplasty repair versus mitral valve replacement. 34,89 -92 Many think undersized annuloplasty is not effective and simply results in MR recurrence 60, 91, 92 ; many others feel that valve repair is the better option for all the reasons previously discussed. 45 We feel that the crux of the issue is the ventricular pathology and physiology. If the dysfunctional ventricle can stop remodeling and even undergo reverse remodeling by removal of the pure volume overload that MR represents, then we think repair will be effective and mitral valve competence long lasting. There is strong evidence that MR recurrence is almost always associated with continued LV remodeling. 92 However, if the dysfunctional ventricle is so dysfunctional that removal of the MR volume overload does not stop remodeling, then we submit that repair of any variety will not be long lasting and that mitral valve replacement should be performed. Any replacement should be performed with complete preservation of the subvalvular apparatus to preserve ventricular function as much as possible. In this circumstance, though the ventricle continues to dilate, there will no longer be any MR. Such a scenario portends very poorly for the patient.
SUMMARY
The mitral valve apparatus is a complex anatomic structure composed of several components, each of which can be affected by a variety of diseases, resulting in MR. We define functional MR as systolic retrograde flow from the LV into the left atrium due to reduction and/or elimination of the normal systolic coaptation of the mitral valve leaflets. The natural history is characterized by slowly progressive symptoms, and often the onset of disabling symptoms is the result of irreversible LV dysfunction. The pathophysiology and treatment of functional MR is complex. Chronic functional MR is a common clinical entity, which will likely increase in the future due to predicted demographic changes. Functional MR is also associated with poor long-term survival.
Optimal medical treatment is obviously required as standard therapy for symptomatic patients. When symptoms persist despite maximal medical therapy, or severe MR exists or LV dysfunction is present, valvular surgery should be considered before LV function becomes further depressed. What this surgery should be-whether replacement or undersized annuloplasty repair-remains a very controversial topic. There is no completely accepted consensus in either the cardiology or cardiac surgery communities, though most surgeons feel that mitral valve repair results in lower perioperative mortality than mitral valve replacement and should therefore likely be the preferred procedure. However, this is far from an accepted viewpoint, and there is no current standard of care. Treatment of the underlying ventricular pathology, if possible, is equally as important as treatment of the valve itself, though it is equally unclear whether treatment of the functional MR will result in correction of the LV remodeling. Functional MR should remain an active area of basic and clinical research to define the optimal treatment strategy and to improve outcomes for a steadily increasing patient population.
